Quantcast

Industry news that matters to you.  Learn more

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

Invivoscribe® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics®, and personalized molecular medicine®, reports that its next-generation sequencing (NGS) LymphoTrack® Assay kits are being used by its LabPMM® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T-cells (CAR-T) and engineered T-cell receptors in peripheral blood of subjects in support of immuno-therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

Epinomics to Collaborate with the Parker Institute for Cancer Immunotherapy at Stanford University to Bring Precision Medicine to Cancer Immunotherapies

Researchers from Epinomics will collaborate with the research team led by Crystal Mackall, MD, director of the Parker Institute for Cancer Immunotherapy at Stanford, to utilize biomarkers defined by Epinomics’ immune intelligence framework to improve outcome and reduce adverse events in immunotherapy clinical trials.

Scientists Discover Why Some Cancers May Not Respond to Immunotherapy

UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or no benefit from the immunotherapy drug pembrolizumab. This early-stage research has allowed them to determine for the first time why some people with advanced melanoma or advanced colon cancer will not respond to pembrolizumab, an anti-PD-1 treatment.

Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

Eli Lilly and Company (NYSE:LLY) and BioNTech AG recently announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.

Ventana Medical Systems, Inc. and MedImmune Collaborate to Develop a Custom PD-L1 Assay for Immunotherapy Clinical Trials

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, recently announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.